Core Insights - Tandem Diabetes Care, Inc. reported 234.42millioninrevenueforQ12025,ayear−over−yearincreaseof22.30.67, compared to -0.63ayearago,indicatingadecline[1]−TherevenueexceededtheZacksConsensusEstimateof220.24 million by 6.44%, while the EPS fell short of the consensus estimate of -0.60by11.6783.79 million, exceeding the average estimate of 74.74million,representingayear−over−yearchangeof+35.472.14 million, slightly above the average estimate of 71.94million,withayear−over−yearincreaseof+16.978.49 million, surpassing the average estimate of 74.32million,reflectingayear−over−yearchangeof+13.529.95 million, below the average estimate of 31.46million,withayear−over−yearchangeof+17.153.84 million, exceeding the average estimate of 43.03million,representingayear−over−yearchangeof+48.1150.63 million, above the average estimate of 146.17million,withayear−over−yearchangeof+16.1150.63 million, compared to the average estimate of 146.45million[4]−Revenuefromsuppliesandotherproductswas132.33 million, exceeding the average estimate of 118.22million[4]−Pumprevenuewas102.09 million, slightly below the average estimate of $102.82 million [4]